|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM362862303 |
| 003 |
DE-627 |
| 005 |
20240531232348.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202303266
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1424.xml
|
| 035 |
|
|
|a (DE-627)NLM362862303
|
| 035 |
|
|
|a (NLM)37792475
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Hu, Mingdi
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Physiological Barriers and Strategies of Lipid-Based Nanoparticles for Nucleic Acid Drug Delivery
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 29.05.2024
|
| 500 |
|
|
|a Date Revised 30.05.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Lipid-based nanoparticles (LBNPs) are currently the most promising vehicles for nucleic acid drug (NAD) delivery. Although their clinical applications have achieved success, the NAD delivery efficiency and safety are still unsatisfactory, which are, to a large extent, due to the existence of multi-level physiological barriers in vivo. It is important to elucidate the interactions between these barriers and LBNPs, which will guide more rational design of efficient NAD vehicles with low adverse effects and facilitate broader applications of nucleic acid therapeutics. This review describes the obstacles and challenges of biological barriers to NAD delivery at systemic, organ, sub-organ, cellular, and subcellular levels. The strategies to overcome these barriers are comprehensively reviewed, mainly including physically/chemically engineering LBNPs and directly modifying physiological barriers by auxiliary treatments. Then the potentials and challenges for successful translation of these preclinical studies into the clinic are discussed. In the end, a forward look at the strategies on manipulating protein corona (PC) is addressed, which may pull off the trick of overcoming those physiological barriers and significantly improve the efficacy and safety of LBNP-based NADs delivery
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a lipid‐based nanoparticles
|
| 650 |
|
4 |
|a physiological barriers
|
| 650 |
|
4 |
|a protein corona
|
| 650 |
|
4 |
|a strategies
|
| 650 |
|
7 |
|a Nucleic Acids
|2 NLM
|
| 650 |
|
7 |
|a Lipids
|2 NLM
|
| 650 |
|
7 |
|a Drug Carriers
|2 NLM
|
| 650 |
|
7 |
|a Protein Corona
|2 NLM
|
| 700 |
1 |
|
|a Li, Xiaoyan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a You, Zhen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cai, Rong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Chunying
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 22 vom: 11. Mai, Seite e2303266
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:22
|g day:11
|g month:05
|g pages:e2303266
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202303266
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 22
|b 11
|c 05
|h e2303266
|